Friday 6 November 2026 Export TXG’s income statement to Excel — free account

10x Genomics

TXG Healthcare Medical Devices

10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.

Revenue: +1.12%
EPS: +31.8%
Free cash flow: −4.61%

Quarter to September 2026, against a year earlier

Operating cash flow growth 3 yrs

58.35 0.29 +0.50%

Follow TXG

Alert me

Market cap: $7.6B
P/E: 0.0×
Fwd P/E: −95.9×
Dividend yield: —
F-score: 6/9
Altman Z: 3.99
Beneish M: −3.23
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

10x Genomics (TXG) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, 10x Genomics (TXG) trades at a P/S ratio of 12.4×. Over the past ten years it has ranged from 0.0× (December 2019) to 66.6× (February 2021); the current reading is higher than 64% of that period. That is above the Medical Devices industry median of 2.5× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/TXG/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="10x Genomics P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/TXG/metrics/ps-ratio">10x Genomics (TXG) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	3.2×	11.77%
FY2024	2.8×	(72.46%)
FY2023	10.3×	32.00%
FY2022	7.8×	(76.76%)
FY2021	33.5×	(30.08%)
FY2020	47.9×	60.95%
FY2019	29.8×	—
FY2018	0.0×	—
FY2017	0.0×	—

Period	P/S ratio	Change
Sep 2026	19.1×	136.53%
Jun 2026	8.1×	89.46%
Mar 2026	4.3×	34.71%
Dec 2025	3.2×	38.47%
27 more quarters	Free account

Against its own ten years

Low 0.0× High 66.6×

Ten-year median 9.5×

Current reading's percentile 62

Company	P/S ratio
SNN Smith & Nephew SNATS, Inc. compare	1.4×
BRKR Bruker Corporation compare	2.5×
PODD Insulet Corporation compare	3.4×
GMED Globus Medical, Inc. compare	3.5×
BIO Bio-Rad Laboratories, Inc. compare	3.8×
BIO.B Bio-Rad Laboratories, Inc. compare	3.9×
HAE Haemonetics Corporation compare	4.1×
PEN Penumbra, Inc. compare	8.1×
TXG 10x Genomics	12.4×
Medical Devices industry median	2.5×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

10x Genomics (TXG) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on TXG

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on TXG

Stockrow Weekly